News | Breast Imaging | November 16, 2021

Improved treatments mean about half of patients live for five years or longer

Patients with two out of the three most common types of advanced breast cancer now have an average survival time of at least five years, according to a panel of experts at the Advanced Breast Cancer Sixth International Consensus Conference (ABC 6)

Professor Fatima Cardoso


November 16, 2021 — Patients with two out of the three most common types of advanced breast cancer now have an average survival time of at least five years, according to a panel of experts at the Advanced Breast Cancer Sixth International Consensus Conference (ABC 6).1 

When breast cancer spreads to other parts of the body (called metastatic or advanced breast cancer), it becomes harder to treat and average survival times have been low as a result. However, over the last ten years, there has been more research on advanced breast cancer (ABC) meaning that doctors now know much more about how to treat the disease.2 

In a session agreeing new guidelines for treating advanced breast cancer, experts said that more work is needed to find treatments that are effective for the third type of ABC (called triple negative ABC), where average survival times remain lower.

The most common subtype of ABC is known as hormonal-dependent or oestrogen receptor-positive (ER+) because its growth is fueled by the hormone oestrogen. Another subtype is known as HER2+ because the cancer cells make too much of a protein known as HER2, which stimulates their growth. In the past decade, the median survival for these two subtypes of ABC, which together make up 85% of cases, has risen from just one or two years to five years. This means that half of patients with these cancers may live for more than five years, with some living for as long as ten years.

The third subtype, known as triple-negative cancer because it is not fueled by oestrogen and it does not over-produce HER2, has fewer treatment options and patients have worse survival as a result. In the last couple of years, hope has risen for this subtype as well, with two new treatments providing some survival benefit. In the new guidelines agreed at ABC 6, experts say that patients with this subtype should have access to these new drugs, sacituzumab govitecan and anti-PD-L1 agents, especially pembrolizumab.

A key objective of the Advanced Breast Cancer Conferences and the ABC Global Alliance, delineated in the ABC Global Charter3, is to double the survival among patients with the disease by 2025. Chair of the ABC 6 Conference and of the ABC Global Alliance, Professor Fatima Cardoso, Director of the Breast Unit of the Champalimaud Cancer Centre in Lisbon, Portugal, said: “We have made a major step towards our goal of doubling average survival times for patients because we have now achieved this in two out of three subtypes of advanced breast cancer.

“This disease is still incurable, but we have come a long way and this progress makes me feel hopeful. It means that for the majority of patients, they have two or three extra years of life, with good quality of life as well. Survival has also improved for patients with triple negative disease, but we need to do more for these patients, especially as it tends to affect younger people who often have young children to care for.”

The Advanced Breast Cancer International Consensus Conferences have been running for a decade, meeting every two years to share and discuss the latest research on ABC, and to update international guidelines on how best to treat patients. The new guidelines from this year’s meeting will be published in early 2022.

Professor Cardoso added, “A decade ago there was a terrible lack of research about how to help patients with advanced breast cancer and, as a result, we had to base most of our recommendations on the opinion of experts.

“We’ve worked hard to galvanize the research community around this issue, and we’ve made major progress over the last ten years. This year, as a result, most of our recommendations for treating ABC are now based on the best possible scientific evidence, called level 1. This is good news for patients because they can be confident that the treatments they are offered are backed by the best science and have the best chance of keeping them well for longer.”

Renata Haidinger, co-chair of ABC 6, president of German Breast Cancer Association and a breast cancer survivor since 2000, said, “Thanks to the leadership and determination of Professor Cardoso, the ABC Conferences and the ABC Global Alliance have made a huge contribution to improvements in the understanding, treatment and survival of advanced breast cancer. Over the last ten years, this has had a tremendous impact on patients’ lives and I have no doubt that with continued work, we will make further improvements to help more patients with metastatic disease survive for five years and beyond.”

The new ABC guidelines also highlighted:

Breast cancer that has limited metastatic lesions and is sensitive to treatment (called oligo-metastatic disease), “has the potential for long survival or cure with a multidisciplinary approach”.

Prof Cardoso said, “This is a message of hope. Due to better systemic treatments and radiotherapy, we can treat locally several types of metastases without causing many other health problems, and we can induce long, complete remissions. We can almost talk about curing although we can never promise, and this only applies to a minority of patients.”

Cancer and treatment-related cognitive impairment (CRCI) or “onco-brain” is a real condition involving physical changes in the brain as a consequence of cancer treatment and should not be dismissed as “just in the mind”. For the first time, the guidelines define the condition and make recommendations for managing it, for example, by routine physical exercise and screening for factors that could be ameliorated or corrected, such as side effects of medications, emotional distress, depression or anxiety, alcohol use and vitamin deficiencies.

For the first time, the guidelines state that patient carers require support too. The experts call for working carers to be protected from discrimination at work, and for them to be entitled to continued employment and reasonable adjustments, such as flexible working, to accommodate their caring responsibilities.

There are no reliable figures for the numbers of women (and men) living with advanced breast cancer. However, there are over two million new cases of breast cancer a year in the world and 0.6 million deaths. About 5-10% of cases are either locally advanced or have metastasized at diagnosis, and these figures reach almost 80% in developing countries. About a third of all early breast cancer cases will become metastatic even with the best care.

 

References

1 Around 1,000 participants from countries all over the world are attending the Advanced Breast Cancer Sixth International Consensus Conference (ABC 6). This year the meeting has moved online from its normal venue in Lisbon, Portugal, due to the COVID-19 pandemic.

2 Advanced breast cancer is defined as cancer that has spread beyond the site of the first (primary) tumor to other sites either surrounding sites such as the skin, chest wall and some lymph nodes (called locally advanced) or distant parts of the body (metastatic cancer).

3https://www.abcglobalalliance.org/abc-global-charter/

 

For more information: abcglobalalliance.org

 

Related Breast Imaging Information:

Black Women Are Receiving Inferior Breast Screening

Hologic Partners with Oprah Winfrey Network to Combat Health Disparities for Black Women

Legislation May Help Identify Breast Cancer Earlier in Certain At-risk Women

Female Breast Cancer Surpasses Lung as the Most Commonly Diagnosed Cancer Worldwide

Johns Hopkins Medicine Expert Weighs Devastating Impact of COVID-19 on Healthcare Workers

Radiation Oncologists Urge Congress to Advance Bills That Protect Patient Access to Cancer Care During Pandemic

Breast Imaging in the Age of Coronavirus

Related Content

Feature | Radiology Imaging | By Melinda Taschetta-Millane

December 8, 2021 — Here is a list of the Top 10 most read pieces of content on ITNonline.com from the month of November ...

Time December 08, 2021
arrow
News | Clinical Trials

December 7, 2021 — IceCure Medical Ltd., developer of minimally-invasive cryoablation technology, the ProSense System ...

Time December 07, 2021
arrow
News | Breast Imaging

December 7, 2021 — According to an open-access article in ARRS’ American Journal of Roentgenology (AJR), screening ...

Time December 07, 2021
arrow
News | Molecular Imaging

December 7, 2021 — An international research team has used the X-ray laser European XFEL to gain new insights into how ...

Time December 07, 2021
arrow
News | Radiology Business

December 6, 2021 — iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy ...

Time December 06, 2021
arrow
News | Radiation Therapy

December 6, 2021 — RefleXion Medical Inc., a therapeutic oncology company, announced that the U.S. Food and Drug ...

Time December 06, 2021
arrow
News | Coronavirus (COVID-19)

December 2, 2021 — Almost two-thirds of U.S. states failed to prioritize cancer patients for COVID-19 vaccinations ...

Time December 02, 2021
arrow
News | Artificial Intelligence

November 28, 2021 — Lunit, a medical AI provider, is returning to the 107th Radiological Society of North America (RSNA) ...

Time November 28, 2021
arrow
News | Breast Imaging

Lunit, a leading medical AI provider, announced that the U.S. Food and Drug Administration (FDA) 510(k) has cleared its ...

Time November 28, 2021
arrow
News | Breast Imaging

November 24, 2021 — Hologic Inc. will showcase its extensive portfolio of breast and skeletal health products, including ...

Time November 24, 2021
arrow
Subscribe Now